Abstract
Objective: To identify novel causes of recessive ataxias, including spinocerebellar ataxia with saccadic intrusions, spastic ataxias, and spastic paraplegia. Methods: In an international collaboration, we independently performed exome sequencing in 7 families with recessive ataxia and/or spastic paraplegia. To evaluate the role of VPS13D mutations, we evaluated a Drosophila knockout model and investigated mitochondrial function in patient-derived fibroblast cultures. Results: Exome sequencing identified compound heterozygous mutations in VPS13D on chromosome 1p36 in all 7 families. This included a large family with 5 affected siblings with spinocerebellar ataxia with saccadic intrusions (SCASI), or spinocerebellar ataxia, recessive, type 4 (SCAR4). Linkage to chromosome 1p36 was found in this family with a logarithm of odds score of 3.1. The phenotypic spectrum in our 12 patients was broad. Although most presented with ataxia, additional or predominant spasticity was present in 5 patients. Disease onset ranged from infancy to 39 years, and symptoms were slowly progressive and included loss of independent ambulation in 5. All but 2 patients carried a loss-of-function (nonsense or splice site) mutation on one and a missense mutation on the other allele. Knockdown or removal of Vps13D in Drosophila neurons led to changes in mitochondrial morphology and impairment in mitochondrial distribution along axons. Patient fibroblasts showed altered morphology and functionality including reduced energy production. Interpretation: Our study demonstrates that compound heterozygous mutations in VPS13D cause movement disorders along the ataxia–spasticity spectrum, making VPS13D the fourth VPS13 paralog involved in neurological disorders. Ann Neurol 2018.
| Originalsprache | Englisch |
|---|---|
| Zeitschrift | Annals of Neurology |
| Jahrgang | 83 |
| Ausgabenummer | 6 |
| Seiten (von - bis) | 1075-1088 |
| Seitenumfang | 14 |
| ISSN | 0364-5134 |
| DOIs | |
| Publikationsstatus | Veröffentlicht - 01.06.2018 |
Fördermittel
Patients were identified in 5 different centers with a focus on movement disorders located at Case Western Reserve University (Cleveland, OH) and genetically analyzed in Ann Arbor (MI, UM1), Nijmegen and Rotterdam (the Netherlands, NIJ1–4), Lu€beck (Germany, LUB1), and Winston-Salem (NC, USA, WF1). Diagnostic testing (including gene panel analysis of known ataxia/spasticity genes) did not reveal a molecular diagnosis in these cases. All patients and relatives gave written informed consent to participate in diagnostic or research studies that were approved by the respective local institutional review boards (Institutional Review Boards of the University of Michigan Medical School, University of Lubeck ethics review panel), or to local (NIJ and Rotterdam) or commercial (WF1; Gen-eDx, Gaithersburg, MD) clinical exome sequencing (NIJ and WF1). Formation of this collaboration was facilitated by publication of grants funded by the National Ataxia Foundation and by GeneMatcher.8 This work was supported by the NIH-NINDS (NS078560, M.B.; NS069844, C.C.; F32NS098611, RI), the National Ataxia Foundation (M.B.), the European Union’s Horizon 2020 research innovation program under ERA-NET Cofund action 643578, ZonMW (9003037604; B.P.v.d.W.) under the framework of the E-Rare-3 network PREPARE, the Hersenstichting (B.P.v.d.W.), Radboud University Medical Center (B.P.v.d.W.), Bioblast Pharma (B.P.v.d.W.), the Foundation of the University Hospital Schleswig-Holstein (“Gutes Tun!”; A.M. and K.L.), and a career development award from the Hermann and Lilly Schilling Foundation (C.K.).
Strategische Forschungsbereiche und Zentren
- Forschungsschwerpunkt: Gehirn, Hormone, Verhalten - Center for Brain, Behavior and Metabolism (CBBM)